A Pharmacokinetics Study of GZR33 Injection at Different Injection Sites

November 15, 2026 updated by: Gan & Lee Pharmaceuticals.

A Randomized, Open-Label, Three-Period Crossover Clinical Study to Evaluate the Pharmacokinetics and Safety of GZR33 Injection Administered at Different Injection Sites in Healthy Participants

This trial is conducted in China. This study will be conducted to evaluate the pharmacokinetics and safety of GZR33 Injection administered at different injection sites in healthy participants.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

24

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Signed the informed consent form (ICF) prior to study procedures, fully understood the study content, procedures and potential adverse reactions, and agreed to comply with the study protocol.
  2. Aged 18 to 45 years (inclusive, based on the date of ICF ); male or female.

Exclusion Criteria:

  1. History of atopic diathesis, or allergic diseases such as bronchial asthma, urticaria, and eczema; known hypersensitivity or intolerance to the investigational product, its analogous products, or excipients.
  2. Positive screening test for any of the following: hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), treponema pallidum antibody (TP-Ab).
  3. Participation in another clinical trial of investigational medicinal products or medical devices with receipt of study treatment within 3 months prior to screening.
  4. Participants who donated blood or blood product (>400 mL) or significant blood loss (>200 mL) within 6 months prior to screening, or plan to donate blood or blood products during the study.
  5. History of substance abuse or illicit drug use within 1 year prior to screening, or positive drug abuse screening test.
  6. Average daily tobacco consumption of more than 5 cigarettes within 3 months prior to screening, or inability to abstain from tobacco-containing products (cigarettes, chewing tobacco, etc.) during the study.
  7. History of vasovagal syncope related to needle or blood exposure, or difficult venous access for blood collection.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: GZR33 Injection-Abdomen

Participants will receive a single-dose administration of GZR33 Injection(s.c. inthe abdomen , the upper arm and the thigh) on different occasions.

Administered subcutaneously (s.c.)

Experimental: GZR33 Injection-Upper Arm

Participants will receive a single-dose administration of GZR33 Injection(s.c. inthe abdomen , the upper arm and the thigh) on different occasions.

Administered subcutaneously (s.c.)

Experimental: GZR33 Injection- Thigh

Participants will receive a single-dose administration of GZR33 Injection(s.c. inthe abdomen , the upper arm and the thigh) on different occasions.

Administered subcutaneously (s.c.)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
AUC₀-₁₂₀ h
Time Frame: 0 hours to 120 hours after study drug administration
0 hours to 120 hours after study drug administration

Secondary Outcome Measures

Outcome Measure
Time Frame
AUC₀-∞
Time Frame: 0 hours to 120 hours after study drug administration
0 hours to 120 hours after study drug administration
Cmax
Time Frame: 0 hours to 120 hours after study drug administration
0 hours to 120 hours after study drug administration

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 16, 2026

Primary Completion (Estimated)

January 15, 2027

Study Completion (Estimated)

January 15, 2027

Study Registration Dates

First Submitted

November 7, 2026

First Submitted That Met QC Criteria

November 15, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 15, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • GZR33-T2D-101

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.